1 / 72

ENDOCRINE CASE STUDIES

ENDOCRINE CASE STUDIES. Dr SUNIL ZACHARIAH Consultant Endocrinologist Spire Gatwick Park and ESH. CASE-1. 23 year old lady 3 months post delivery Presents with palpitations and loose stools FT4=32.6 pmol/L TSH<0.01 mU/L. POSTPARTUM THYROIDITIS.

eron
Télécharger la présentation

ENDOCRINE CASE STUDIES

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ENDOCRINE CASE STUDIES Dr SUNIL ZACHARIAH Consultant Endocrinologist Spire Gatwick Park and ESH

  2. CASE-1 • 23 year old lady • 3 months post delivery • Presents with palpitations and loose stools • FT4=32.6 pmol/L • TSH<0.01 mU/L

  3. POSTPARTUM THYROIDITIS • Incidence varies from 5-11% • More common in women with a family history of hypothyroidism and positive TPO antibodies

  4. CLINICAL FEATURES • Presentation is usually 3-4 months postpartum • Can be hypothyroidism (40%), hyperthyroidism (40%) or biphasic(20%) • Goiter is present in 50% of patients • To distinguish from Graves disease use thyroid isotope scan and TSH receptor Ab

  5. Pathogenesis • Destructive autoimmune thyroiditis causing first release of thyroxine and then hypothyroidism as the thyroid reserve is depleted • FNAC shows lymphocytic thyroiditis

  6. Management • Most patients recover spontaneously without requiring treatment • If hyperthyroid use beta blockers rather than antithyroid drugs as the problem is increased release, not synthesis • Hypothyroid phase is more likely to require treatment • Only 3-4% remain permanently hypothyroid • 10-25% will recur in future pregnancies

  7. Case Study-2 • 60 year old Type 2 Diabetes • Last HbA1c=8%(64 mmol/mol) • Presents with erectile dysfunction • Not much benefit from Viagra • Testosterone level 8 nmol/L

  8. Hypogonadism in Type 2 Diabetes • Low testosterone levels are common in people with type 2 diabetes • Effect of testosterone replacement on glycaemic control remains uncertain • If androgen deficiency is suspected then do at least two 9 am testosterone levels. If first sample is low , then check LH, FSH, SHBG, ferritin and prolactin as well in the 2nd sample

  9. If testosterone level is between 8 and 12 nmol/L in a symptomatic individual, then a trial of testosterone replacement is warranted • If the man has tried a phosphodiesterase inhibitor without success and has a total testosterone of <12 nmol/L, then a 6 month trial of testosterone is warranted

  10. Case Study 3 • 27 year old female • Follicular Cancer of Thyroid • Post surgery, post radioiodine ablation • On Thyroxine replacement (175 mcg) • FT4 19.8 • TSH 0.05

  11. Follow up of thyroid Cancer • Original diagnosis and treatment • If total thyroidectomy and ablative radioiodine, thyroglobulins usually undetectable if TSH unrecordable • Maintain TSH<0.05

  12. Case 4 • 50 year old man • Ventricular tachycardia with poor LV function • Controlled on Amiodarone • FT4 50 • FT3 7 • TSH<0.01

  13. Amiodarone and Thyroid • Inhibits thyroidal iodide uptake • Inhibits conversion of T4 to T3 intracellularly • Inhibits T4 entry into cells • Direct T3 antagonism at level of cardiac tissue

  14. Amiodarone induced hyperthyroidism • 2-12% • Type 1: Iodine overload in abnormal gland, treat with carbimazole or lithium • Type 2: Glandular damage, release of preformed hormones, treat with prednisolone 0.5-1.25 mg/kg for 3-6 weeks • Management of tachyarrhythmia's: beta blockers if not in CCF • ?total thyroidectomy (not radioiodine)

  15. CASE 5 • 32 year old female • BMI=25 • Detected to have blood pressure of 210/100 mm Hg • History of palpitations, abdominal discomfort • Investigated for secondary causes of hypertension

  16. 24hr Urinary collections

  17. L.L. CT Scan 1998

  18. L.L. MIGB Scan 1998

  19. Management of Phaeochromocytoma • Commenced on alpha and beta blockade • Referred for surgery

  20. DEFINITION • Phaeochromocytomas are adrenomedullary catecholamine secreting tumours • Paragangliomas are tumours arising from extra-adrenal medullary neural crest derivatives, e.g. sympathetic or carotid body, aorticopulmonary, intravagal or parasympathetic

  21. INCIDENCE • Rare tumours • Accounting for <0.1% of causes of hypertension • Can be fatal if undiagnosed

  22. EPIDEMIOLOGY • Equal sex distribution • Most commonly in 3rd and 4th decades • Majority(90%) are sporadic, 10% are inherited

  23. PATHOPHYSIOLOGY • Sporadic tumours are usually unilateral and <10 cm diameter • 10-20% are malignant • Paragangliomas are more likely to be malignant

  24. CLINICAL FEATURES • Sustained or episodic hypertension • Sweating and heat intolerance(80%) • Headache(65%) • Palpitations(65%) • Abdominal pain • Constipation

  25. COMPLICATIONS • CVS: LVF, dilated cardiomyopathy • Resp: Pulmonary oedema • Neuro: Cerebrovascular, hypertensive encephalopathy

  26. Who should be screened? • Family history of MEN, VHL, Neurofibromatosis • Paroxysmal symptoms • Young hypertensive • Patient developing HT crisis during GA • Unexplained heart failure

  27. INVESTIGATIONS • 24 hour urine collection for catecholamines. Because of episodic nature at least two 24 hour samples • Plasma catecholamines: Limited use because of intermittent secretion. Useful if patient having a crisis • Screening for associated conditions

  28. LOCALIZATION • MRI or CT scan • MIBG scan: Meta-iodobenzylguanidine is a chromaffin-seeking analogue. Positive in 60-80%.

  29. MANAGEMENT • Alfa-blockade (Phenoxybenzamine) must be commenced before beta-blockade to avoid precipitating a hypertensive crisis due to unopposed alfa-adrenergic stimulation • Surgical resection (open or laparoscopic) • Malignancy: High dose MIBG therapy, Chemotherapy, Octreotide therapy

  30. Case Study 6 • 49 year old • HGV Driver • Diagnosed type 2 diabetes 8 years ago • Diet controlled for 1 year • Check’s Blood Glucose once a day (8-13) • On tablets since then • Yearly retinal screening

  31. MEDICATIONS • Metformin 1 gm bd • Pioglitazone 45 mg od • Gliclazide 80 mg bd • Lipitor 40 mg od • Perindopril 4 mg od • Aspirin 75 mg od

  32. Hba1c=9.2% • Creatinine=90, GFR=76 • ?Next Step

  33. * * * * * * * * * * The incretin effect is reduced in patients with type 2 diabetes Intravenous Glucose Oral Glucose Control subjects Patients with type 2 diabetes 80 80 60 60 Insulin (mU/L) Insulin (mU/L) 40 40 20 20 0 0 0 30 60 90 120 150 180 0 30 60 90 120 150 180 Time (min) Time (min) *P ≤.05 compared with respective value after oral load. Nauck MA, et al. Diabetologia 1986;29:46–52.

  34. Ingestion of food • Glucose dependent • Insulin from beta cells(GLP-1 and GIP) Insulinincreases peripheral glucose uptake GI tract Pancreas Release of incretin gut hormones Beta cells Alpha cells Active GLP-1 and GIP Increased insulin and decreasedglucagon reduce hepatic glucose output • Glucagon from alpha cells (GLP-1)Glucose dependent Incretins and glycaemic control Bloodglucose control DPP-4enzyme rapidly degrades incretins Adapted from 7. Drucker DJ. Cell Metab. 2006;3:153–165. 8. Miller S, St Onge EL. Ann Pharmacother 2006;40:1336-1343.

  35. CASE STUDY-7 • 88 year old lady • Diarrhoea • Abdominal pain • Weight loss

  36. PAST MEDICAL HISTORY • Extensive Investigations for Chronic Diarrhoea(5 years) • Diverticular disease • Hypothyroidism • Hypertension • Ischemic Heart Disease • Hysterectomy

  37. EXAMINATION • Mildly dehydrated • Hypotensive (94/60 mm Hg) • Abdomen: Tenderness in Epigastrium and RUQ • CVS: Soft Systolic murmur

  38. INVESTIGATIONS • Hb: 12.9 Bilirubin: 5 • WBC: 14.5 ALT: 61 • MCV: 90 Alk PO4: 417 • Platelets: 461 Albumin: 42 • Sodium: 134 GammaGT: 533 • Potassium: 3.6 TSH: 3.3 • Urea: 12.6 Ft4: 12 • Creatinine: 90 T3: 3.2 • CRP: 138 Calcium: 2.4

  39. Urine analysis: NAD • Stool Culture, toxins and microscopy: Negative

  40. IMAGING • CXR: Normal • Ultrasound Abdomen: Hepatomegaly, with multiple avascular, iso-echoic lesions in both lobes of liver representing metastasis. Primary likely to be ?colorectal or ?pulmonary

  41. PATIENT PROGRESS • Discussion with patient and family • Options discussed • Patient not keen on further invasive tests • Agreed for CT scan

  42. CT Scan • No significant lymphadenopathy • No significant lung lesions • Liver is replaced by multiple metastasis in both lobes • Normal pancreas and adrenals • No masses in the ovary or large bowel

  43. TUMOUR MARKERS • CEA: 4.9 (0-15) • CA-125: 55 (0-35) • CA 19-9: 64 (0-27)

  44. PROGRESS • Diarrhoea persisting • General condition of patient, however good • History reviewed with patient: Feeling flushed for many months • Could this be Carcinoid?

  45. 24 hour 5 HIAA requested • Laboratory reluctant • Result: 672 (Normal<31) • Diagnosis of Carcinoid syndrome made • Referral to Oncology and Endocrine team made

  46. TREATMENT • Octreotide injections started • Discharged with District Nurse input and Oncology follow up

  47. EPIDEMIOLOGY • Annual incidence: 1/100000 population • Mean age: 50-60 years • Males=Females • Increased risk of developing other carcinoma’s

More Related